This study examined the use of a commercial, medical-grade honey (MGH) product for treating otic infections to determine if it would be an effective alternative to conventional therapies. Client-owned dogs (n = 15) with confirmed infectious otitis externa were enrolled and administered 1 mL of MGH once a day in each affected ear until clinical cure was achieved or until the end of the 21-day study.
Because of reports that MGH can be ototoxic, examinations were performed before enrollment to ensure integrity of the tympanic membrane in all participants. Clinical otitis scores, cytologic examination, and owner assessments of pruritus were collected during weekly examinations. Samples were submitted for microbial culture and susceptibility testing. Results showed that 70% of dogs achieved clinical cure between days 7 and 14, and >90% achieved clinical resolution by day 21. Clinical otitis scores and owner assessments of pruritus decreased significantly over the course of the study, with 75% of owners indicating they were very satisfied with treatment.
Laboratory testing showed that MGH demonstrated clear biocidal activity against all bacterial isolates in the first 5 minutes of contact (±10 seconds) in vitro. Treatment was satisfactorily tolerated by all participants. The authors concluded that the MGH product studied has potential as an alternative treatment, although larger, randomized, controlled studies are needed.